Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Heparin Could Reduce Neurologic Deterioration Following Stroke

By HospiMedica International staff writers
Posted on 27 Aug 2012
Following an acute ischemic stroke, low-molecular weight heparin (LMWH) may help prevent early neurologic deterioration in patients with large artery occlusive disease (LAOD), according to a new study. More...


Researchers at the Prince of Wales Hospital (Hong Kong SAR, China) conducted a post-hoc analysis of a randomized, controlled, trial involving 353 patients following acute ischemic stroke and LAOD. The patients were randomly assigned to receive either subcutaneous LMWH (180 patients) or oral aspirin (173 patients) within 48 hours after stroke onset for 10 days; following intervention, all patients received aspirin once daily for six months. The main outcome measure was the prevention of early neurologic deterioration (END) within the first 10 days after index stroke.

The analysis showed that END occurred in 12 of the heparin group patients (6.7%) and 24 of the aspirin group patients (13.9%). The 7.2 percentage point difference yielded an odds ratio of 0.44 in favor of heparin. When the researchers looked at the individual components of their endpoint, they found that stroke progression within the first 10 days was 5% with heparin and 12.7% with aspirin, leading to an odds ratio of 0.36. The rates of early recurrent ischemic stroke (ERIS) and intracranial cerebral hemorrhage were not significantly different, as were the rates of other cerebral hemorrhages, both symptomatic and asymptomatic. The study was published in the August 13, 2012, issue of Archives of Neurology.

“For patients with acute ischemic stroke and LAOD, treatment with LMWH within 48 hours of stroke may reduce END during the first 10 days, mainly by preventing stroke progression,” concluded lead author Ka Sing Lawrence Wong, MD, and colleagues. “The similar rate of cerebral hemorrhage between LMWH and aspirin demonstrated that LMWH may be safely used in acute ischemic stroke.”

Patients with acute ischemic stroke and LAOD have an increased risk for early neurologic deterioration due to progressive stroke, ERIS, or symptomatic intracranial cerebral hemorrhage (SICH). LMWH has been widely advocated to prevent venous thromboembolism, but its risks and benefits in early ischemic stroke are inadequately defined.

Related Links:

Prince of Wales Hospital




Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Fetal Monitor
BT-380
New
Immobilization System
Cranial 4Pi Immobilization
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Six-month FlexPulse IDE data show positive outcomes with Abbott’s TactiFlex Duo catheter, confirming safety and efficacy seen in the CE Mark study for complex AFib (photo courtesy of Abbott)

Dual-Energy Ablation and Conduction System Pacing Show Positive Early Outcomes

Atrial fibrillation and other arrhythmias are common in both hospitalized and ambulatory patients, often complicating hemodynamic stability, stroke prevention, and perioperative care. Within this context,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.